‘120 pages of data’: Roche’s pipeline review leads to asset cuts, but also additions

Reynald Castañeda

Deputy Editor

Roche disclosed on Wednesday it had cut several early- to mid-stage candidates after a broader R&D review, which also saw pipeline additions and triggered recently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘120 pages of data’: Roche’s pipeline review leads to asset cuts, but also additions

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

‘120 pages of da­ta’: Roche’s pipeline re­view leads to as­set cuts, but al­so ad­di­tions

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

‘120 pages of data’: Roche’s pipeline review leads to asset cuts, but also additions

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena